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Abstract 
Background: Diabetes is the western world’s leading cause of end-stage renal disease. Glucose-dependent, oxida-
tive stress is linked to the development of renal inflammation and sclerosis, which, in animal models of diabetes, can 
be prevented by anti-oxidative treatment. Patients of non-Caucasian heritage have low activity of the selenoprotein, 
antioxidant enzyme, glutathione peroxidase (GPx) and its co-factor vitamin E, which may be linked to their increased 
propensity to developing end-stage renal disease.
Research design and methods: We have designed a double-blind, randomized, placebo controlled study with 
selenium and/or vitamin E versus placebo as the interventions for patients with type 2 diabetes and chronic kidney 
disease (CKD) stages 1–3. A 2 × 2 factorial design will allow a balanced representation of the heritage groups exposed 
to each intervention. The primary biochemical outcome is change in GPx activity, and clinical outcome measure is 
the actual, rate of—and/or percentage change in estimated glomerular filtration rate (eGFR) from baseline. Analysis 
will be with a marginal model for longitudinal data using Generalized Estimating Equations corrected for measures of 
baseline serum antioxidant enzyme activities (GPx, superoxide dismutase and catalase), micronutrient levels (vitamins 
E and C), measures of inflammation (interleukin 6, c-reactive protein and monocyte chemoattractant protein-1) and 
markers of oxidative damage (plasma 8-isoprostaglandin F2α and urinary 8-hydroxydeoxyguanosine).
Expected results: The study will assess the relationship between GPx activity, oxidative stress, inflammation and 
eGFR. It will test the null hypothesis that antioxidant therapy does not influence the activity of GPx or other antioxi-
dant enzymes and/or alter the rate of change in eGFR in these patient groups.
Conclusions: Outcome data on the effect of antioxidants in human diabetic renal disease is limited. Previous post 
hoc analyses have not shown a beneficial effect of vitamin E on renal function. A recent trial of a pharmaceutical 
antioxidant agent, improved eGFR, but in patients with advanced diabetes-related chronic kidney disease its use was 
associated with an increased incidence of cardiovascular events. We will explore whether the nutritional antioxidants, 
vitamin E and selenium alone, or in combination in patients at high risk of renal disease progression, forestalls a reduc-
tion in eGFR. The study will describe whether endogenous antioxidant enzyme defenses can be safely modified by 
this intervention and how this is associated with changes in markers of oxidative stress.
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Background
Diabetes is the leading cause of end-stage renal disease 
(ESRD) which has a predilection for persons of non-white 
heritage [1]. Comparative international, and national 
studies suggest that the rate of progression of chronic 
kidney disease (CKD) is higher in patients of non-white 
heritage than those of Caucasian heritage [1–3]. In a post 
hoc analysis of the United Kingdom Prospective Study, 
an independent relationship was found between non-
white ethnic heritage, albuminuria and renal impairment 
[4]. These observational data suggest that heritable and/
or shared environmental factors play a role in the sus-
ceptibility to, and progression of renal disease in patients 
with diabetes.
Hyperglycaemia increases the production of reac-
tive oxygen species (ROS) which are capable of damag-
ing lipid and DNA molecules. Oxidative stress occurs 
when ROS production overwhelms the host’s capac-
ity to remove them which then causes upregulation in 
transcription factors such as NF-κB and elaboration of 
pro-inflammatory cytokines and chemokines. These bio-
chemical events limit the availability of the vasodilator 
nitric oxide, which interferes with the regulation of blood 
flow and vasoprotective functions of the endothelium [5]. 
In experimental studies, these changes have been shown 
to be determinants of the development of diabetic kid-
ney lesions which can be ameliorated with antioxidant 
treatment. In a rodent model of type 2 diabetes and kid-
ney disease, vitamin E given as an antioxidant therapy, 
restored antioxidant enzyme activity and reduced oxi-
dative damage of renal tissue [6]. This has led to sugges-
tions that strategies to enhance endogenous antioxidant 
mechanisms could help prevent microvascular diabetic 
complications [7].
Markers of oxidative stress are increased in the circula-
tion and renal tissue of patients with diabetes compared 
with control patients without diabetes [8, 9]. Patients of 
African origin have been found to have higher circulating 
levels of lipid peroxide, lower concentrations of vitamin 
E and faster rates of decline in renal function compared 
with those of Caucasian heritage [10, 11]. Relatively low 
levels of serum selenium have been reported in people 
of Asian origin [12]. Selenium is a co-factor for the anti-
oxidant enzyme GPx, and low levels are associated with 
an upregulation of inflammatory chemokines. Selenium 
supplementation attenuates the inflammatory response 
and in systemic inflammatory disease states may improve 
clinical outcomes [13, 14].
The activity of GPx in plasma is largely derived from 
renal tubular epithelium and is reduced in the presence 
of renal disease [15, 16]. It is unclear whether the level 
of activity of GPx contributes to the susceptibility to 
progressive renal disease. In this study, we will compare 
the effect over time of antioxidant therapy with vitamin 
E and/or selenium in patients with type 2 diabetes and 
early CKD, on measures of systemic inflammation, anti-
oxidant enzyme activity and changes in eGFR.
Subjects
We plan to recruit a total of 200 adult patients with type 
2 diabetes of white, Caucasian and non-Caucasian (Afri-
can, Caribbean or Indo-Asian) heritage from general 
practices in South West London, UK. An equal number 
of eligible patients will be randomized to receive, either, 
active selenium (200  μg once daily) or its placebo and/
or vitamin E (400 IU once daily) or its placebo in a 2 × 2 
factorial design (Fig.  1). Treatment allocation will be 
according to a computer generated code for each group 
to which the patients and researchers will be blinded.
Type 2 diabetes mellitus will be diagnosed according to 
WHO criteria. Eligible patients will have hypertension (3 
consecutive sitting blood pressure readings >140 systolic 
and/or diastolic 90 mmHg without treatment or receiv-
ing treatment for known hypertension) and early CKD 
defined as an eGFR > 45 and <90 mL/min/1.73 m2 and/or 
urinary albumin:creatinine ratio >3 mg/mmol.
Patients will be excluded if they have any of the follow-
ing: a history of cardiovascular disease, defined as having 
a clinical record of ischaemic heart disease (angina, myo-
cardial infarction, coronary artery revascularization and 
or heart failure), peripheral vascular disease (intermittent 
claudication or peripheral artery revascularization) or 
cerebrovascular disease (transient ischaemic episodes or 
stroke), a history of malignancy or any other life threat-
ening illness, current pregnancy, systolic blood pres-
sure >200 mmHg, diastolic blood pressure >160 mmHg, 
haemoglobin A1c > 86 mmol/mol (10 %), significant renal 
impairment (eGFR < 45 mL/min 1.73 m2) and nephrotic 
range urine protein excretion (total protein excretion 
rate  >3  g/day or albumin:creatinine ratio  >300  mg/
mmol).
The medical, family, social and treatment histories, and 
the clinical and biochemical measurements collected at 
the in-person visits will be recorded using a standard-
ized, electronic proforma. Dietary intake and patterns 
will be evaluated using a 3-day food diary to assess com-
ponents of the usual diet (Dietplan 6, Forestfield Software 
Ltd, Horsham, West Sussex, UK).
Methods
Anthropometric measures will include height in metres, 
weight in kilogrammes, and waist circumference in cen-
timetres. Body mass index will be calculated from the 
weight in kilogrammes divided by the height in metres 
squared. Sitting blood pressure will be measured by digi-
tal oscillometry (Omron 705IT, OMRON Healthcare 
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Europe, The Netherlands) according to the National 
Institutes of Health and Care Excellence guidance (http://
www.nice.org.uk/guidance/cg127).
Patients will undergo routine clinical assessments for 
the complications of diabetes. The presence or absence 
of retinopathy will be reviewed on an annual basis by 
standardized, digital retinal fundal photography which 
will be reported according to National Health Service 
guidelines by retinal screeners who are unaware of the 
patient’s participation in the study (http://www.dia-
beticeye.screening.nhs.uk/gradingcriteria). Peripheral 
neuropathy will be assessed according to responses to 
testing with a 10  g monofilament. Peripheral vascular 
disease will be assessed by the appreciation of the dor-
salis pedis and posterior tibial artery pulsation by digital 
examination. Patients will also be screened for ischaemic 
heart disease in response to modified questions from 
the Rose questionnaire [17] and have 12-lead resting 
electrocardiography (Seca CardioConcept 5.6, Seca UK) 
performed and read using Novacode criteria [18].
Arterial stiffness
Finger plethysmography is a non-invasive method to 
assess changes in finger blood flow that will be used as a 
proxy measure of arterial stiffness. The pulse wave ampli-
tude will be measured from the finger-tip using infra-red 
light (PulseTrace PCA2, CareFusion UK 232 Ltd, Basing-
stoke). The contour of the finger pulse will then be auto-
matically analysed to determine a stiffness index which 
has been shown to be correlate with pulse wave velocity 
after adjustment age, sex, height, and weight [19].
Biochemical assessments
Venous blood will be sampled after a 12  h fast. Meas-
urements will be performed to allow several domains 
of the study to be addressed, including lipids, systemic 
inflammation, oxidative damage and stress, diabetes con-
trol and nutrition. Deoxyribonucleic acid (DNA) will be 
extracted from whole blood using a salting-out method 
as described by Miller et al. [20] for the subsequent analy-
sis of genetic polymorphisms of the antioxidant enzymes 
being investigated.
Plasma creatinine will be used to estimate renal func-
tion—using the modification of diet in renal disease 
(MDRD) and CKD-EPI equations. Three early morn-
ing urine samples will be collected for estimation of the 
median albumin: creatinine ratio. Aliquots of the urine, 
whole blood and blood separated into serum and plasma 
will be stored at −70 to −80  °C for later analysis of the 
key outcome variables described below.
Glutathione peroxidase activity will be measured 
as described previously by Zitouni et  al. [11]. In brief, 
500  μL Tris–HCl (0.2  mmol/L, pH 8) will be mixed 
with NADPH (0.2  mmol) followed by 100  μL EDTA 
(5 mmol/L) and 100 μL glutathione (20 mmol/L). Plasma 
(100  μL) will then be mixed with glutathione reductase 
(0.002 units) and incubated for 5 min at 37 °C and for a 
further 5  min after the addition of 100  μL of tert-butyl 
hydroperoxide (0.7 mmol/L). Absorbances will be read in 
a spectrophotometer at 340 nm. A unit of GPx activity is 
defined as being equivalent to the oxidation of 1 μmol of 
NADPH per second at 37 °C. The intra-assay coefficient 
of variation (c.v.) is 3.2 %.
Catalase activity in plasma will be measured using a 
fluorometric assay. Plasma (50  μL) will be mixed with 
400  μL phosphate buffer (100  mmol, pH 7) followed by 
50  μL horseradish peroxidase (40  U/ml) and 100  μL of 
hydrogen peroxide (3.3 μmol/L). The samples will then be 
vortex-mixed and incubated for 10 min at room temper-
ature. After incubation, 50  μL of hydroxyphenyl acetate 
(50  mg/mL) will be added and the fluorescence of the 
Placebo vitamin E 
Placebo selenium 
Active vitamin E 
Active selenium 
Placebo vitamin E 
Active selenium 
Placebo selenium 
Active vitamin E 
Patients with Type 2 Diabetes with an 
increased risk of progressive CKD 
Eligible patients from different heritage groups  
screened and consented 
White Caucasian African and 
Indo-Asian
Eligible patients from each heritage group 
randomized to one of 4 possible 
interventions for 24 months 
Diabetes Registers of General Practices 
in South West London, UK  
Fig. 1 Flow diagram of the recruitment, randomization and follow-
up of eligible patients double-blind, randomized placebo controlled 
trial into the 2 × 2 factorial, to achieve balanced representation of 
non-Caucasian and Caucasian heritage groups
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product will be read in a fluorometer (excitation 320 nm 
and emission 400 nm). Within-run c.v.’s are 2 % for stand-
ards and samples, whereas the between-run c.v. are 3.1 % 
for standards and 7.3 % for samples.
Extracellular SOD activity will be measured in rela-
tion to the inhibition of the rate of nitro blue tetrazolium 
(NBT) reduction in the presence of xanthine and xanthine 
oxidase yielding a purple colour [11]. Plasma (500  μL) 
will be treated with 300 μL chloroform and 500 μL etha-
nol. The samples will then be centrifuged at 18,000 ×  g 
for 30 min, and 50 μL of the supernatant will be removed 
and mixed with 900 μL of SOD reagent [0.1 mmol/L xan-
thine, 0.1 mmol/L EDTA, 50 mg bovine serum albumin, 
25  mmol/L NBT and 40  mmol/L Na2CO3 (pH 10.2)]. 
Twenty-five units of xanthine oxidase will then be added, 
and the samples will be incubated for 20 min at 25 °C. The 
reaction will be stopped by the addition of 1  mL CuCl2 
(0.8 mmol/L), and the absorbance of the samples will be 
measured at 560 nm. The intra-assay c.v. is 3.5 %.
Vitamin E as plasma α- and γ-tocopherols will be meas-
ured using a high-performance liquid chromatography 
system with ultraviolet detection and tocopherol acetate 
as internal standard. Briefly, plasma (100 μL) will be com-
bined with 3 μg α-tocopherol acetate and 500 μL hexane. 
The upper layer will be aspirated after centrifugation, 
and lipid extraction will be performed twice. The solvent 
will be evaporated to dryness under a stream of nitrogen. 
The residue will be dissolved into 400 μL methanol and 
20 μL will be injected onto the high performance liquid 
chromatography system. α-Tocopherol and γ-tocopherol 
concentrations in the samples will be calculated by relat-
ing their peak areas to that of the internal standard. The 
plasma contents of absolute and lipid standardized vita-
min E will be expressed relative to triglyceride, choles-
terol, or triglyceride and cholesterol.
The total cholesterol content of plasma will be meas-
ured by an enzymatic colorimetric method (Cholesterol 
CHOD-PAP; Sigma Diagnostic). Briefly, an aliquot of 
plasma sample (10 µL) will be incubated with a reagent 
(900 µL) containing: detergent, cholesterol esterase, and 
cholesterol oxidase. Hydrogen peroxide produced as a 
result of cholesterol oxidase activity is used to oxidise 
aminoantipyrene to give a pink product, the absorption 
of which will be measured in a spectrophotometer at 
500 nm.
The total triglyceride contents of plasma and lipo-
protein fractions will be measured by an enzymatic 
colorimetric method (Triglycerides GPO-PAP; Sigma 
Diagnostics). In brief, an aliquot of plasma sample (10 µL) 
will be mixed with 900 µL of a reagent containing a lipase 
to deacylate triglycerides and liberate glycerol. This will 
then be phosphorylated to glucose-1-phosphate and 
the product oxidised by glucose phosphate oxidase with 
the formation of hydrogen peroxide (H2O2). The H2O2 
formed will then be coupled with horseradish peroxidase 
to give a pink product, the absorption of which will be 
measured in a spectrophotometer at 500 nm.
Vitamin C as total ascorbate (sum of oxidised and 
reduced ascorbate) will be measured by enzymatic oxida-
tion of reduced ascorbic acid to dehydroascorbate acid 
followed by reaction of the dehydroascorbate formed 
with o-phenylenediamine to give a fluorescent product 
[21]. Two hundred and fifty microliters of plasma will be 
mixed with 250 μL metaphosphoric acid (20 % w/v) and 
centrifuged at 13 000×g for 5  min. 50  μL of the super-
natants will be combined with 900 μL of sodium acetate 
buffer (2 mol/L, pH 6.2) and ascorbate oxidase (10 μL of 
1  U/1  μL in sodium acetate buffer). o-1, 2-diphenylen-
ediamine (20 μL, 1 mg/mL) is then added and the sam-
ples are incubated for 30 min at room temperature in the 
dark. Finally, the fluorescent signals will be read in spec-
trofluorometer at excitation at emission wavelengths of 
350 and 430 nm, respectively. The inter- and intra-assay 
c.v. are 1 and 2.5 %, respectively.
Selenium will be measured in serum as described by 
Rayman et al. [22]. The analysis will be carried out at the 
SAS Trace Element Unit, Southampton General Hospital 
using dynamic reaction cell-inductively coupled plasma 
MS on an Elan 6100 DRC plus (SCIEX Perkin-Elmer).
Oxidative stress will be assessed by measuring (1) 
plasma and urinary free 8-iso prostaglandin F2α using 
an ELISA kit (Cayman Chemical, Ann Arbor, MI, USA) 
and (2) urinary 8-hydroxydeoxyguanosine (8-OHdG) as a 
marker of deoxyribonucleic acid damage using an ELISA 
kit according to the manufacturer’s instructions (Cam-
bridge Biosciences Ltd, Cambridge, UK).
Inflammation will be assessed by measuring c-reactive 
protein, interleukin-6 and monocyte chemoattractant 
protein-1 by ELISA kits according to the manufacturer’s 
instructions (ThermoFisher Scientific, Paisley, UK).
Clinical follow‑up procedures
All patients will receive their usual care according to the 
latest National Institutes of Clinical Excellence recom-
mendations, in primary and secondary care settings [23]. 
Treatment will aim to achieve targets for blood pressure 
of ≤130/80  mmHg, glycated haemoglobin of 59  mmol/
mol (<7.5  %) and LDL-cholesterol of  ≤2  mmol/L 
(<100 mg/dL). Routine clinical and biochemical measure-
ments and outcome assessments will be performed at the 
baseline visit and 1, 3, 6, 12, 18 and 24 months after ran-
domization. All of the patient’s data will be anonymized.
Statistical analysis
In this 2  ×  2 factorial design, selenium and vitamin E 
are considered the two factors. The data will be analyzed 
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with a linear mixed model for longitudinal data [24]. In 
the model, eGFR is the dependent variable and time is an 
independent variable; the model will also contain as inde-
pendent variables a dummy variable for each of the two 
factors, a term for the two-way interaction between the 
two factors, and continuous covariates for various meas-
ures of oxidative stress and inflammation at baseline. 
The model allows for the correlation between repeated 
measures on the same individual, but assumes that there 
is independence from one subject to the next. The cor-
relation within measurements on a given subject will be 
modeled using compound symmetry as well as an autore-
gressive correlation structure. Whichever structure gives 
the best fitting model to the data will be used.
Results
The primary hypothesis of interest in this study is 
whether there is an interaction between the selenium and 
Vitamin E supplements. If interaction is present, then the 
effect of each supplement will have to be estimated sepa-
rately in the presence and absence of the other supple-
ment. If no interaction is present, then it will be possible 
to estimate the main effects of selenium and Vitamin E 
separately without having to take the other supplement 
into consideration.
The effect sizes are conservative and will be based on 
the estimated changes from baseline to 1  year [25]. A 
study population of 150 will have 85  % power to detect 
an ES of 1.0 SD, and a population of 200 will have 83 % 
power to detect an ES of 0.85 SD at a two-sided alpha 
level of 5 % [26].
The two heritage groups will have their eGFR slopes 
compared over time and considered as either, (a) Cau-
casian and non-Caucasian, or (b) High and Low levels of 
oxidative stress/inflammation, with the oxidative stress 
and inflammation markers dichotomized at their median 
value. The power will not be heavily dependent on any 
of the assumptions; regardless of the true value of the 
underlying correlation among observations with subjects, 
of the correlation structure, of the attrition rate, or of the 
number of repeated measurements.
Discussion
Chronic kidney disease is a world-wide, major pub-
lic health concern which, depending upon classifica-
tion codes affects up to 1:3 patients with type 2 diabetes 
[27]. Chronic kidney disease is a costly complication of 
diabetes. In the United Kingdom, it has been estimated 
that 10 % of its £110 billion ($183 billion USD) healthcare 
budget is spent managing diabetes and £1.5 ($2.5 billion) 
on CKD and renal replacement therapy [28].
There has been a reduction in ESRD over the last 
decade which may be related to better management of 
traditional risk factors [29]. However, diabetes remains 
the leading cause of ESRD and has a striking predilec-
tion for persons of non-white heritage. The 2014 United 
Renal Data System reported that in 2012, the incidence 
of ESRD amongst persons with diabetes of African (non-
Caucasian) heritage was fourfold greater compared with 
those of white (Caucasian) origin. Of interest, the report 
reveals that between 2007 and 2012 there was a differ-
ence of only 2 % in the prevalence of CKD between the 
groups. Some of the difference in kidney disease progres-
sion is explained by the relatively higher rates of hyper-
tension and proteinuria in the patients of African origin, 
but is unrelated to variations in access to healthcare 
before dialysis [30]. However, 1:3 patients with diabetes 
at risk of CKD may not have increased urinary protein 
excretion [31]. In the United Kingdom Prospective Dia-
betes Study, in which patients were followed-up from the 
diagnosis of type 2 diabetes, racial heritage was found to 
be an independent determinant of renal dysfunction [32]. 
And, recently, it has been reported that inflammatory 
stress, has a stronger relationship than albuminuria with 
early CKD in patients with diabetes of African heritage, 
compared with other heritage groups [33].
A large experimental evidence base supports the role 
of inflammatory and oxidative stress in the development 
of kidney lesions in diabetes. However, clinical data con-
cerning the effect of antioxidant therapy in preventing 
renal (and vascular disease) is conflicting. Several stud-
ies suggest that vitamin E in non-diabetic patients with 
high levels of oxidative stress has a beneficial impact on 
hypertension-related disorders and reduces biochemical 
markers of oxidation [34, 35]. However, post hoc analy-
ses of some antioxidant trials did not show any effect on 
cardiovascular or renal end-points [36, 37]. It is possible 
that prevalent, systemic vascular damage might mitigate 
any benefit of antioxidant treatment. Furthermore, these 
analyses have not related clinical outcomes to actual 
measures of vitamin E or other evaluations of oxidant 
and/or antioxidant status.
There is some evidence that vitamin E suppresses albu-
minuria in patients with diabetes, preserved renal func-
tion and without cardiovascular disease [38]. Moreover, 
patients with high oxidant stress due to genetically deter-
mined low levels of the antioxidant haptoglobin, who 
received vitamin E, had a significantly reduced incidence 
of vascular events compared to controls [39]. In a rodent 
model of type 2 diabetes, treatment with tocotrienol-rich 
fractions improved glycemic status, serum lipid profile 
and renal function in association with restoration of anti-
oxidant enzyme activity [40]. These data suggest that, 
oxidative stress promotes renal and vascular damage that 
may be ameliorated by an antioxidant intervention in 
those patients at highest risk of their development.
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Previously, we found GPx activity to be lower in patients 
with type 2 diabetes of African heritage compared with 
Caucasians. Others have shown that low GPx activity is 
associated with an accelerated development of vascular 
lesions in both experimental rodent models, and patients 
with diabetes [41, [42]. However, data are limited on the 
role of GPx activity or its regulation with respect to the 
development or progression of renal disease in patients 
with diabetes. The PREVENT trial will provide new infor-
mation on whether progression of the early stages of 
CKD, is related to, or modified by, oxidative stress and/or 
host antioxidant defense mechanisms in type 2 diabetes.
Conclusions
In animal models of diabetes, there is overwhelming 
experimental evidence for a role of oxidative stress in 
renal pathophysiology. However, most clinical reports of 
antioxidant therapy have been post hoc analyses of sur-
rogate markers, in non-specific populations with con-
flicting outcomes and safety concerns. We will primarily 
address renal functional decline in patients with diabetes 
at high risk of progressive disease. Importantly, it will 
investigate whether a nutraceutical approach to modulate 
an endogenous antioxidant pathway is safe and effective. 
The outcomes will help improve our understanding of the 
translation of oxidative metabolism in the development 
and treatment of renal disease.
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